ClinicalTrials.gg
CompletedNCT01193335Updated May 11, 2017Results posted

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

A Phase 4 interventional study of 13-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in 13-valent Pneumococcal Vaccine, Premature Birth and Immunization, sponsored by Pfizer. Completed at 12 sites in 2 countries. Open to participants aged 42 Days to 98 Days. Per ClinicalTrials.gov, last updated 2017-05-11.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
42 Days to 98 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Premature Birth with a site in Poland — 3 open to participants now, 3 under way, none of them phase 3. Premature Birth · Poland.

Enrollment
4th of 16
200 · median 53
Started
2010
the only one that year
Phase 4
Only one
of the 23
Registered
3rd of 23
by date

Among the 23 studies in Premature Birth with a site in Poland, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2010, is the only one in phase 4, and was the 3rd registered.

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 503 are open to participants now.

Browse Premature Birth studies →

Open to participants now

3 of the 23 studies in Premature Birth with a site in Poland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 315 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 223 (71%) stop at 75 or younger; 241 take children under 18; 105 take healthy volunteers.

This study: 42 Days to 98 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Premature Birth with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study is to describe the safety, tolerability, and immunogenicity of a 2,3,4 and 12 month schedule of the 13-valent pneumococcal conjugate vaccine when given to preterm infants with concomitant vaccines, compared to infants born at term.There will be a follow-up phase to assess the persistence of the antibody response at 24 and 36 months of age.

03

Conditions studied

  • 13-valent Pneumococcal Vaccine
  • Premature Birth
  • Immunization
  • Safety

Browse trials for

Keywords

  • 13-valent pneumococcal conjugate vaccine
  • premature
  • immunization
  • safety.
04

Who can participate

Ages eligible
42 Days to 98 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Infants between 42 and 98 days of age (approximately 2 months) at the time of enrollment.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with pneumococcal vaccine,Haemophilus influenzae type B (Hib) conjugate vaccine, meningococcal type C conjugate vaccine, or diphtheria, tetanus, pertussis, or poliovirus vaccines.
  • Previous anaphylactic reaction or allergy to any vaccine
  • to vaccination
  • Known or suspected immune deficiency or immune suppression
  • Major known congenital malformation or serious chronic disorder
  • Significant neurological disorder
  • Participation to another study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Group 1: Preterm infants

    Infant born at \< 37 weeks of gestation.

    Biological: 13-valent pneumococcal conjugate vaccine

  • Active comparator
    Group 2: Term infants

    Infants born at ≥ 37 weeks of gestation

    Biological: 13-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After Infant Series

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: 1 month after the infant series

  2. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series

    Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after the infant series

  3. Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 1 Infant Series

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 1 of the infant series

  4. Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 2 Infant Series

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 2 of the infant series

  5. Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 3 Infant Series

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 3 of the infant series

  6. Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Toddler Dose

    Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after the toddler dose

  7. Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 1 Infant Series

    Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 1 of the infant series

  8. Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 2 Infant Series

    Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 2 of the infant series

  9. Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 3 Infant Series

    Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after Dose 3 of the infant series

  10. Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Toddler Dose

    Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

    Time frame: Within 7 days after the toddler dose

  11. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Infant Series

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Dose 1 up to 1 month after Dose 3 (infant series)

  12. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): After Infant Series

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: 1 Month after Dose 3 of the infant series up to toddler dose

  13. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Toddler Dose

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Toddler dose up to 1 Month after toddler dose

  14. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 1-Year Follow-up After Toddler Dose

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: 1 month after toddler dose up to 1-year follow-up

  15. Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 2-Year Follow-up After Toddler Dose

    An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: 1-year follow-up after toddler dose to 2-year follow-up after toddler dose

Secondary outcomes

  1. Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Toddler Pre-Dose to 1 Month After Toddler Dose

    GMFR for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) from before 13vPnC toddler dose to 1 month after 13vPnC toddler dose were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC toddler dose and after 13vPnC toddler dose blood draws.

    Time frame: Before 13vPnC Toddler Dose (pre-vaccination), 1 month after 13vPnC Toddler Dose

  2. Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After Infant Series: Group 1A, 1B, 1C

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 % CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: 1 Month After Infant Series

  3. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG antibody concentration to the given serotype for each arm, respectively.

    Time frame: 1 month after the toddler dose

  4. Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level >=0.35 mcg/mL 1 Month After Toddler Dose: Group 1A, 1B, 1C

    Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants.

    Time frame: 1 month after the toddler dose

  5. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose

    Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: Before Toddler Dose (pre-vaccination)

  6. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose

    Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: 1 Month After Toddler Dose

  7. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose

    The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 Year After Toddler Dose

  8. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose

    The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 2 Years After Toddler Dose

  9. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Infant Series: Group 1A, 1B, 1C

    Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: 1 Month After Infant Series

  10. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose: Group 1A, 1B, 1C

    Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: Before Toddler Dose (pre-vaccination)

  11. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose: Group 1A, 1B, 1C

    Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

    Time frame: 1 Month After Toddler Dose

  12. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose: Group 1A, 1B, 1C

    The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 Year After Toddler Dose

  13. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose: Group 1A, 1B, 1C

    The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 2 Years After Toddler Dose

  14. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Infant Series

    Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

    Time frame: 1 Month After Infant Series

  15. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Before Toddler Dose

    Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

    Time frame: Before the toddler dose (pre-vaccination)

  16. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Toddler Dose

    Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

    Time frame: 1 Month After Toddler Dose

  17. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Year After Toddler Dose

    Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

    Time frame: 1 Year After Toddler Dose

  18. Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 2 Years After Toddler Dose

    Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

    Time frame: 2 Years After Toddler Dose

  19. Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series

    Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

    Time frame: 1 Month After Infant Series

  20. Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) Before Toddler Dose

    Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

    Time frame: Before Toddler Dose (pre-vaccination)

  21. Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Toddler Dose

    Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

    Time frame: 1 Month After Toddler Dose

  22. Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Year After Toddler Dose

    Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

    Time frame: 1 Year After Toddler Dose

  23. Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 2 Years After Toddler Dose

    Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

    Time frame: 2 Years After Toddler Dose

07

Results

Posted Feb 4, 2015

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Started100100
Completed100100
Not completed00
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Started100100
Completed9997
Not completed13
Withdrew: Lost to follow-up12
Withdrew: No longer met eligibility criteria01
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Started9997
Completed9997
Not completed00
1-Year Follow-up
Participant flow — 1-Year Follow-up
Milestone13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Started9997
Completed8888
Not completed119
Withdrew: No longer willing to participate79
Withdrew: Lost to follow-up40
2-Year Follow-up
Participant flow — 2-Year Follow-up
Milestone13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Started8888
Completed8180
Not completed78
Withdrew: No longer willing to participate56
Withdrew: No longer met eligibility criteria22

Outcome measures

PrimaryPercentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After Infant Series

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 percent (%) confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
1 month after the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n=99, 97)96.97 (91.40 to 99.37)98.97 (94.39 to 99.97)
6B (n=99, 97)72.73 (62.85 to 81.20)87.63 (79.39 to 93.44)
9V (n=99, 97)96.97 (91.40 to 99.37)96.91 (91.23 to 99.36)
14 (n=99, 97)100.00 (96.34 to 100.00)97.94 (92.75 to 99.75)
18C (n=99, 97)96.97 (91.40 to 99.37)94.85 (88.38 to 98.31)
19F (n=99, 97)98.99 (94.50 to 99.97)98.97 (94.39 to 99.97)
23F (n=99, 97 )85.86 (77.41 to 92.05)92.78 (85.70 to 97.05)
1 (n=99, 97)93.94 (87.27 to 97.74)95.88 (89.78 to 98.87)
3 (n=99, 97)85.86 (77.41 to 92.05)90.72 (83.12 to 95.67)
5 (n=99, 97)71.72 (61.78 to 80.31)90.72 (83.12 to 95.67)
6A (n=98, 97)82.65 (73.69 to 89.56)94.85 (88.38 to 98.31)
7F (n=99, 97)98.99 (94.50 to 99.97)98.97 (94.39 to 99.97)
19A (n=99, 97)98.99 (94.50 to 99.97)98.97 (94.39 to 99.97)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -2.00 · 95% CI -7.65 to 2.88
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -14.90 · 95% CI -26.40 to -3.21
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.06 · 95% CI -5.84 to 6.05
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 2.06 · 95% CI -1.71 to 7.25
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 2.12 · 95% CI -4.09 to 8.89
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.02 · 95% CI -4.54 to 4.68
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -6.92 · 95% CI -16.19 to 1.89
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.94 · 95% CI -9.07 to 4.86
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -4.86 · 95% CI -14.40 to 4.39
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -19.00 · 95% CI -30.10 to -7.16
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -12.19 · 95% CI -21.66 to -3.26
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.02 · 95% CI -4.54 to 4.68
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.02 · 95% CI -4.54 to 4.68
PrimaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series

Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs for GMC were back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after the infant series
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series
mcg/mL13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n=99, 97)1.96 (1.67 to 2.31)2.46 (2.04 to 2.97)
6B (n=99, 97)0.73 (0.55 to 0.97)1.30 (1.00 to 1.67)
9V (n=99, 97)1.26 (1.08 to 1.47)1.70 (1.45 to 2.00)
14 (n=99, 97)7.48 (6.23 to 8.99)6.08 (4.82 to 7.67)
18C (n=99, 97)1.93 (1.66 to 2.24)1.93 (1.62 to 2.29)
19F (n=99, 97)2.21 (1.89 to 2.58)3.05 (2.62 to 3.55)
23F (n=99, 97)0.86 (0.69 to 1.07)1.36 (1.10 to 1.68)
1 (n=99, 97)1.26 (1.06 to 1.48)1.79 (1.50 to 2.13)
3 (n=99, 97)0.83 (0.70 to 0.98)0.86 (0.75 to 1.00)
5 (n=99, 97)0.56 (0.44 to 0.70)1.03 (0.87 to 1.22)
6A (n=98, 97)1.22 (0.98 to 1.53)2.01 (1.65 to 2.46)
7F (n=99, 97)2.14 (1.81 to 2.53)3.02 (2.63 to 3.48)
19A (n=99, 97)2.85 (2.44 to 3.33)3.35 (2.85 to 3.94)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.80 · 95% CI 0.62 to 1.02
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.56 · 95% CI 0.38 to 0.82
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.74 · 95% CI 0.59 to 0.93
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 1.23 · 95% CI 0.92 to 1.65
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 1.00 · 95% CI 0.80 to 1.25
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.72 · 95% CI 0.58 to 0.90
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.64 · 95% CI 0.47 to 0.86
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.70 · 95% CI 0.55 to 0.89
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.96 · 95% CI 0.77 to 1.19
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.54 · 95% CI 0.40 to 0.72
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.61 · 95% CI 0.45 to 0.82
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.71 · 95% CI 0.57 to 0.88
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.85 · 95% CI 0.68 to 1.07
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 1 Infant Series

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 1 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 1 Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Tenderness- Any (n=94, 88)48.942.0
Tenderness- Mild (n=93, 88)46.231.8
Tenderness- Moderate (n=90, 85)17.816.5
Tenderness- Severe (n=86, 85)0.00.0
Swelling- Any (n=94, 89)39.429.2
Swelling- Mild (n=91, 89)37.428.1
Swelling- Moderate (n=91, 85)8.88.2
Swelling- Severe (n=86, 85)0.00.0
Redness- Any (n=92, 87)33.729.9
Redness- Mild (n=90, 87)32.228.7
Redness- Moderate (n=88, 85)3.44.7
Redness- Severe (n=86, 85)0.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 2 Infant Series

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 2 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 2 Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Tenderness- Any (n=85, 88 )48.238.6
Tenderness- Mild (n=85, 84)43.531.0
Tenderness- Moderate (n=77, 83)14.315.7
Tenderness- Severe (n=73, 77)0.01.3
Swelling- Any (n=84, 82)35.742.7
Swelling- Mild (n=83, 82)33.742.7
Swelling- Moderate (n=75, 76)8.02.6
Swelling- Severe (n=73, 76)0.00.0
Redness- Any (n=82, 82)28.040.2
Redness- Mild (n=82, 82)28.037.8
Redness- Moderate (n=73, 76)2.72.6
Redness- Severe (n=73, 76)0.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 3 Infant Series

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 3 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Dose 3 Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Tenderness- Any (n=82, 84)39.028.6
Tenderness- Mild (n=81, 84)35.826.2
Tenderness- Moderate (n=75, 78)9.35.1
Tenderness- Severe (n=73, 77)0.00.0
Swelling- Any (n=83, 85)30.141.2
Swelling- Mild (n=82, 85)26.841.2
Swelling- Moderate (n=75, 79)5.35.1
Swelling- Severe (n=73, 77)0.00.0
Redness- Any (n=82, 87)32.946.0
Redness- Mild (n=82, 87)32.946.0
Redness- Moderate (n=74, 79)1.43.8
Redness- Severe (n=73, 77)0.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Toddler Dose

Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Mild (hurts if gently touched with no crying); Moderate (hurts if gently touched with crying); Severe (causes limitation of limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\>7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Local Reactions Within 7 Days After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Tenderness- Any (n=86, 85)69.855.3
Tenderness- Mild (n=86, 85)66.351.8
Tenderness- Moderate (n=77, 70)20.811.4
Tenderness- Severe (n=74, 69)2.70.0
Swelling- Any (n=81, 80)43.235.0
Swelling- Mild (n=80, 79)38.832.9
Swelling- Moderate (n=76, 74)13.29.5
Swelling- Severe (n=74, 69)1.40.0
Redness- Any (n=85, 83)51.849.4
Redness- Mild (n=85, 83)51.848.2
Redness- Moderate (n=75, 75)6.710.7
Redness- Severe (n=74, 69)0.00.0
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 1 Infant Series

Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 1 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 1 Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Fever >=38 degrees C (n=86, 88)11.613.6
Fever >=38 degrees C, =<39 degrees C (n=86, 88)10.513.6
Fever >=39 degrees C, =<40 degrees C (n=86, 85)1.20.0
Fever >40 degrees C (n=86, 85)0.00.0
Decreased Appetite- Any (n=92, 89)60.941.6
Decreased Appetite- Mild (n=91, 88)54.935.2
Decreased Appetite- Moderate (n=88, 87)20.517.2
Decreased Appetite- Severe (n=86, 85)1.20.0
Increased Sleep- Any (n=96, 95)67.769.5
Increased Sleep- Mild (n=96, 93)60.461.3
Increased Sleep- Moderate (n=87, 88)29.930.7
Increased Sleep- Severe (n=86, 85)2.32.4
Irritability or Decreased Sleep- Any (n=95, 97)84.282.5
Irritability or Decreased Sleep- Mild (n=93, 95)77.469.5
Irritability or Decreased Sleep-Moderate (n=92, 9143.547.3
Irritability or Decreased Sleep- Severe (n=86, 85)8.15.9
Use of Antipyretic Medication (n=90, 90)24.424.4
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 2 Infant Series

Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 2 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 2 Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Fever >=38 degrees C (n=79, 79)27.831.6
Fever >=38 degrees C, =<39 degrees C (n=79, 79)27.830.4
Fever >=39 degrees C, =<40 degrees C (n=73, 76)0.01.3
Fever >40 degrees C (n=73, 76)0.00.0
Decreased Appetite- Any (n=89, 84)61.846.4
Decreased Appetite- Mild (n=88, 84)55.741.7
Decreased Appetite- Moderate (n=79, 78)25.319.2
Decreased Appetite- Severe (n=73, 76)1.40.0
Increased Sleep- Any (n=85, 89 )74.164.0
Increased Sleep- Mild (n=83, 88)69.959.1
Increased Sleep- Moderate (n=78, 78)34.629.5
Increased Sleep- Severe (n=73, 76)2.71.3
Irritability or Decreased Sleep- Any (n=95, 95)89.577.9
Irritability or Decreased Sleep- Mild (n=90, 92)81.171.7
Irritability or Decreased Sleep-Moderate (n=85, 8664.744.2
Irritability or Decreased Sleep- Severe (n=74, 76)17.62.6
Use of Antipyretic Medication (n=84, 83)48.845.8
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 3 Infant Series

Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after Dose 3 of the infant series
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Dose 3 Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Fever >=38 degrees C (n=79, 81)27.830.9
Fever >=38 degrees C, =<39 degrees C (n=78, 81)26.930.9
Fever >=39 degrees C, =<40 degrees C (n=75, 78)1.32.6
Fever >40 degrees C (n=74, 77)0.00.0
Decreased Appetite- Any (n=82, 84)48.847.6
Decreased Appetite- Mild (n=82, 84)36.646.4
Decreased Appetite- Moderate (n=74, 79)17.616.5
Decreased Appetite- Severe (n=74, 77)1.41.3
Increased Sleep- Any (n=88, 88 )52.358.0
Increased Sleep- Mild (n=88, 87)48.951.7
Increased Sleep- Moderate (n=77, 80)16.920.0
Increased Sleep- Severe (n=73, 77)1.41.3
Irritability or Decreased Sleep- Any (n=92, 95)79.381.1
Irritability or Decreased Sleep- Mild (n=90, 91)72.274.7
Irritability or Decreased Sleep-Moderate (n=80,87)33.835.6
Irritability or Decreased Sleep- Severe (n=74, 78)6.86.4
Use of Antipyretic Medication (n=84, 81)40.538.3
PrimaryPercentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Toddler Dose

Systemic events (fever \>=38 degrees Celsius \[C\], decreased appetite, increased sleep, and irritability or decreased sleep) and use of antipyretic medication were reported using an electronic diary. Decreased appetite was scaled as Any; Mild (loss of appetite but no decreased oral intake); Moderate (decreased oral intake); Severe (refusal to feed). Increased sleep was scaled as Any; Mild (increased or prolonged sleeping bouts); Moderate (slightly subdued interfering with daily activity); Severe (disabling not interested in usual daily activity). Irritability or decreased sleep was scaled as Any; Mild (easily consolable); Moderate (requiring increased attention); Severe (inconsolable; crying that cannot be comforted). Participants may be represented in more than 1 category.

Time frame:
Within 7 days after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-Specified Systemic Events Within 7 Days After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
Fever >=38 degrees C (n= 80, 78)28.843.6
Fever >=38 degrees C, =<39 degrees C (n=80, 77)27.542.9
Fever >=39 degrees C, =<40 degrees C (n=74, 71)1.44.2
Fever >40 degrees C (n=74, 70)0.01.4
Decreased Appetite- Any (n=87, 86)57.560.5
Decreased Appetite- Mild (n=86, 84)50.056.0
Decreased Appetite- Moderate (n=78, 73)25.623.3
Decreased Appetite- Severe (n=75, 69)1.31.4
Increased Sleep- Any (n=83, 86 )57.865.1
Increased Sleep- Mild (n=82, 84)53.759.5
Increased Sleep- Moderate (n=76, 74)18.424.3
Increased Sleep- Severe (n=74, 70)0.02.9
Irritability or Decreased Sleep- Any (n=90, 91)84.480.2
Irritability or Decreased Sleep- Mild (n=90, 89)74.476.4
Irritability or Decreased Sleep-Moderate (n=78,80)44.945.0
Irritability or Decreased Sleep- Severe (n=76, 69)6.64.3
Use of Antipyretic Medication (n=82, 79)48.850.6
PrimaryPercentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Infant Series

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Dose 1 up to 1 month after Dose 3 (infant series)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
AEs59.055.0
SAEs14.05.0
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.668
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.051
PrimaryPercentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): After Infant Series

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
1 Month after Dose 3 of the infant series up to toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): After Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
AEs18.015.0
SAEs8.09.0
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.704
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = >0.99
PrimaryPercentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Toddler Dose

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
Toddler dose up to 1 Month after toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
AEs31.326.8
SAEs2.01.0
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.531
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = >0.99
PrimaryPercentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 1-Year Follow-up After Toddler Dose

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
1 month after toddler dose up to 1-year follow-up
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 1-Year Follow-up After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
AEs15.28.2
SAEs13.18.2
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.183
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.357
PrimaryPercentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 2-Year Follow-up After Toddler Dose

An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. SAE: an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

Time frame:
1-year follow-up after toddler dose to 2-year follow-up after toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs): 2-Year Follow-up After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
AEs8.010.2
SAEs6.89.1
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.794
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Fisher Exact · p = 0.782
SecondaryGeometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Toddler Pre-Dose to 1 Month After Toddler Dose

GMFR for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) from before 13vPnC toddler dose to 1 month after 13vPnC toddler dose were computed using the logarithmically transformed assay results. CIs for GMFR were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the fold rises. GMFRs were calculated using all participants with available data from both before 13vPnC toddler dose and after 13vPnC toddler dose blood draws.

Time frame:
Before 13vPnC Toddler Dose (pre-vaccination), 1 month after 13vPnC Toddler Dose
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Toddler Pre-Dose to 1 Month After Toddler Dose
fold rise13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 83, 85)8.14 (6.61 to 10.04)9.61 (7.77 to 11.88)
6B (n=80, 85)9.46 (7.81 to 11.45)7.61 (6.31 to 9.18)
9V (n=83, 85)5.85 (5.05 to 6.78)4.92 (4.22 to 5.74)
14 (n=83, 85)4.50 (3.76 to 5.38)4.65 (3.82 to 5.65)
18C (n=83, 85)7.36 (6.29 to 8.61)9.14 (7.61 to 10.98)
19F (n=83, 85)10.82 (8.88 to 13.17)12.31 (9.77 to 15.51)
23F (n=79, 83)10.11 (8.13 to 12.57)10.15 (8.32 to 12.39)
1 (n=83, 85)8.41 (6.94 to 10.20)9.98 (8.18 to 12.17)
3 (n=81, 84)7.61 (5.79 to 10.01)5.23 (4.22 to 6.49)
5 (n=80, 85)3.47 (3.04 to 3.97)3.46 (2.93 to 4.09)
6A (n=83, 85)10.52 (8.75 to 12.64)7.72 (6.18 to 9.65)
7F (n=83, 85)5.81 (5.12 to 6.61)6.07 (5.16 to 7.13)
19A (n=83, 85)6.45 (5.39 to 7.72)5.59 (4.53 to 6.90)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 0.85 · 95% CI 0.63 to 1.14
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.24 · 95% CI 0.95 to 1.62
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.19 · 95% CI 0.96 to 1.47
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 0.97 · 95% CI 0.74 to 1.26
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 0.80 · 95% CI 0.63 to 1.02
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 0.88 · 95% CI 0.65 to 1.19
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.00 · 95% CI 0.74 to 1.33
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 0.84 · 95% CI 0.64 to 1.11
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.46 · 95% CI 1.03 to 2.05
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.00 · 95% CI 0.81 to 1.24
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.36 · 95% CI 1.02 to 1.82
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 0.96 · 95% CI 0.78 to 1.18
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmfr ratio: 1.15 · 95% CI 0.88 to 1.52
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After Infant Series: Group 1A, 1B, 1C

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95 % CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
1 Month After Infant Series
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After Infant Series: Group 1A, 1B, 1C
percentage of participants13vPnC Group 1A13vPnC Group 1B13vPnC Group 1C
4 (n=24, 50, 25)100.00 (85.75 to 100.00)96.00 (86.29 to 99.51)96.00 (79.65 to 99.90)
6B (n=24, 50, 25)79.17 (57.85 to 92.87)72.00 (57.51 to 83.77)68.00 (46.50 to 85.05)
9V (n=24, 50, 25)95.83 (78.88 to 99.89)98.00 (89.35 to 99.95)96.00 (79.65 to 99.90)
14 (n=24, 50, 25)100.00 (85.75 to 100.00)100.00 (92.89 to 100.00)100.00 (86.28 to 100.00)
18C (n=24, 50, 25)100.00 (85.75 to 100.00)94.00 (83.45 to 98.75)100.00 (86.28 to 100.00)
19F (n=24, 50, 25)100.00 (85.75 to 100.00)98.00 (89.35 to 99.95)100.00 (86.28 to 100.00)
23F (n=24, 50, 25)91.67 (73.00 to 98.97)80.00 (66.28 to 89.97)92.00 (73.97 to 99.02)
1 (n=24, 50, 25)100.00 (85.75 to 100.00)92.00 (80.77 to 97.78)92.00 (73.97 to 99.02)
3 (n=24, 50, 25)87.50 (67.64 to 97.34)86.00 (73.26 to 94.18)84.00 (63.92 to 95.46)
5 (n=24, 50, 25)79.17 (57.85 to 92.87)66.00 (51.23 to 78.79)76.00 (54.87 to 90.64)
6A (n=24, 49, 25)95.83 (78.88 to 99.89)81.63 (67.98 to 91.24)72.00 (50.61 to 87.93)
7F (n=24, 50, 25)100.00 (85.75 to 100.00)98.00 (89.35 to 99.95)100.00 (86.28 to 100.00)
19A (n=24, 50, 25)100.00 (85.75 to 100.00)98.00 (89.35 to 99.95)100.00 (86.28 to 100.00)
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants. Here 'n' signifies participants with a determinate IgG antibody concentration to the given serotype for each arm, respectively.

Time frame:
1 month after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 mcg/mL 1 Month After the Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
6B (n=86, 87)97.67 (91.85 to 99.72)100.00 (95.85 to 100.00)
9V (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
14 (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
18C (n=86, 87)100.00 (95.80 to 100.00)98.85 (93.76 to 99.97)
19F (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
23F (n=86, 87)98.84 (93.69 to 99.97)100.00 (95.85 to 100.00)
1 (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
3 (n=85, 87)70.59 (59.71 to 79.98)79.31 (69.29 to 87.25)
5 (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
6A (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
7F (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
19A (n=86, 87)100.00 (95.80 to 100.00)100.00 (95.85 to 100.00)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -2.33 · 95% CI -8.15 to 1.96
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 1.15 · 95% CI -3.13 to 6.24
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.16 · 95% CI -6.32 to 3.10
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -8.72 · 95% CI -21.93 to 4.42
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.25 to 4.31
SecondaryPercentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level >=0.35 mcg/mL 1 Month After Toddler Dose: Group 1A, 1B, 1C

Percentage of participants achieving predefined antibody threshold \>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. Exact 2-sided CI based on the observed proportion of participants.

Time frame:
1 month after the toddler dose
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level >=0.35 mcg/mL 1 Month After Toddler Dose: Group 1A, 1B, 1C
percentage of participants13vPnC (Group 1A)13vPnC (Group 1B)13vPnC (Group 1C)
4 (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
6B (n=21, 45, 20)100.00 (83.89 to 100.00)95.56 (84.85 to 99.46)100.00 (83.16 to 100.00)
9V (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
14 (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
18C (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
19F (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
23F (n=21, 45, 20)100.00 (83.89 to 100.00)97.78 (88.23 to 99.94)100.00 (83.16 to 100.00)
1 (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
3 (n=21, 44, 20)95.24 (76.18 to 99.88)68.18 (52.42 to 81.39)50.00 (27.20 to 72.80)
5 (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
6A (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
7F (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
19A (n=21, 45, 20)100.00 (83.89 to 100.00)100.00 (92.13 to 100.00)100.00 (83.16 to 100.00)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose

Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
Before Toddler Dose (pre-vaccination)
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose
mcg/mL13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 85, 85)0.31 (0.26 to 0.37)0.41 (0.34 to 0.49)
6B (n= 82, 85)0.48 (0.39 to 0.58)0.94 (0.79 to 1.11)
9V (n= 85, 85)0.39 (0.33 to 0.46)0.62 (0.53 to 0.72)
14 (n= 85, 85)2.02 (1.68 to 2.43)2.36 (1.94 to 2.87)
18C (n=85, 85)0.32 (0.28 to 0.37)0.30 (0.26 to 0.36)
19F (n=85, 85)0.68 (0.57 to 0.80)0.93 (0.79 to 1.10)
23F (n=81, 83)0.24 (0.18 to 0.31)0.40 (0.33 to 0.48)
1 (n=85, 85)0.39 (0.34 to 0.46)0.41 (0.35 to 0.48)
3 (n=84, 84)0.07 (0.05 to 0.09)0.11 (0.09 to 0.14)
5 (n=82, 85)0.74 (0.64 to 0.87)1.06 (0.90 to 1.26)
6A (n=85, 85)0.54 (0.45 to 0.65)1.01 (0.82 to 1.24)
7F (n=85, 85)0.72 (0.63 to 0.82)0.84 (0.73 to 0.96)
19A (n=85, 85)0.86 (0.72 to 1.03)1.57 (1.27 to 1.92)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.76 · 95% CI 0.60 to 0.97
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.51 · 95% CI 0.39 to 0.66
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.64 · 95% CI 0.51 to 0.80
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.86 · 95% CI 0.66 to 1.12
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 1.06 · 95% CI 0.85 to 1.32
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.73 · 95% CI 0.58 to 0.92
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.60 · 95% CI 0.43 to 0.83
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.96 · 95% CI 0.77 to 1.20
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.60 · 95% CI 0.41 to 0.87
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.70 · 95% CI 0.56 to 0.88
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.54 · 95% CI 0.41 to 0.70
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.86 · 95% CI 0.71 to 1.03
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.55 · 95% CI 0.42 to 0.72
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose

Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
1 Month After Toddler Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose
mcg/mL13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 86, 87)2.57 (2.18 to 3.03)3.97 (3.32 to 4.74)
6B (n=86, 87)4.42 (3.64 to 5.37)7.27 (6.09 to 8.68)
9V (n=86, 87)2.30 (1.99 to 2.66)3.06 (2.62 to 3.56)
14 (n=86, 87)9.24 (7.66 to 11.14)11.02 (9.44 to 12.86)
18C (n=86, 87)2.37 (2.02 to 2.79)2.81 (2.32 to 3.40)
19F (n=86, 87)7.38 (6.23 to 8.76)11.67 (9.47 to 14.36)
23F (n=86, 87)2.45 (2.01 to 2.98)4.03 (3.36 to 4.85)
1 (n=86, 87)3.32 (2.83 to 3.89)4.09 (3.42 to 4.89)
3 (n=85, 87)0.52 (0.44 to 0.62)0.57 (0.49 to 0.65)
5 (n=86, 87)2.63 (2.28 to 3.02)3.72 (3.19 to 4.33)
6A (n=86, 87)5.64 (4.86 to 6.54)7.84 (6.59 to 9.33)
7F (n=86, 87)4.25 (3.75 to 4.82)5.13 (4.48 to 5.87)
19A (n=86, 87)5.57 (4.66 to 6.65)8.84 (7.45 to 10.48)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.65 · 95% CI 0.51 to 0.82
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.61 · 95% CI 0.47 to 0.79
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.75 · 95% CI 0.61 to 0.93
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.84 · 95% CI 0.66 to 1.07
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.84 · 95% CI 0.66 to 1.08
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.63 · 95% CI 0.48 to 0.83
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.61 · 95% CI 0.46 to 0.79
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.81 · 95% CI 0.64 to 1.03
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.92 · 95% CI 0.73 to 1.15
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.71 · 95% CI 0.58 to 0.87
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.72 · 95% CI 0.57 to 0.90
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.83 · 95% CI 0.69 to 1.00
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.63 · 95% CI 0.49 to 0.81
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose

The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 Year After Toddler Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose
mcg/mL13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 80, 79)0.30 (0.25 to 0.36)0.37 (0.31 to 0.44)
6B (n=80, 80)1.26 (1.02 to 1.57)2.01 (1.69 to 2.39)
9V (n=80, 80)0.61 (0.48 to 0.78)0.98 (0.82 to 1.19)
14 (n=79, 80)1.43 (1.15 to 1.78)1.73 (1.40 to 2.14)
18C (n=80, 79)0.33 (0.27 to 0.41)0.66 (0.54 to 0.81)
19F (n=80, 79)0.96 (0.80 to 1.15)1.78 (1.40 to 2.26)
23F (n=79, 80)0.59 (0.47 to 0.74)1.24 (1.01 to 1.52)
1 (n=78, 80)0.40 (0.35 to 0.46)0.53 (0.45 to 0.62)
3 (n=78, 78)0.13 (0.10 to 0.17)0.22 (0.16 to 0.30)
5 (n=79, 78)1.10 (0.91 to 1.32)1.63 (1.35 to 1.97)
6A (n=80, 79)1.08 (0.89 to 1.32)1.59 (1.34 to 1.90)
7F (n=79, 80)0.68 (0.59 to 0.80)0.83 (0.72 to 0.96)
19A (n=80, 80)1.61 (1.22 to 2.12)3.16 (2.53 to 3.95)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.81 · 95% CI 0.63 to 1.04
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.63 · 95% CI 0.48 to 0.83
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.62 · 95% CI 0.46 to 0.84
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.83 · 95% CI 0.61 to 1.12
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.50 · 95% CI 0.37 to 0.67
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.54 · 95% CI 0.40 to 0.72
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.47 · 95% CI 0.35 to 0.64
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.76 · 95% CI 0.61 to 0.94
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.59 · 95% CI 0.39 to 0.90
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.67 · 95% CI 0.52 to 0.87
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.68 · 95% CI 0.52 to 0.88
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.82 · 95% CI 0.67 to 1.02
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.51 · 95% CI 0.36 to 0.72
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose

The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
2 Years After Toddler Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose
mcg/mL13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n=70, 71)0.19 (0.16 to 0.23)0.24 (0.20 to 0.29)
6B (n=70, 70)1.44 (1.13 to 1.85)2.70 (2.10 to 3.48)
9V (n=71, 70)0.74 (0.58 to 0.94)0.99 (0.80 to 1.23)
14 (n=70, 71)1.06 (0.78 to 1.43)1.37 (1.03 to 1.82)
18C (n=69, 71)0.32 (0.24 to 0.42)0.57 (0.47 to 0.69)
19F (n=71, 70)1.10 (0.83 to 1.46)2.43 (1.71 to 3.44)
23F (n=71, 71)1.03 (0.77 to 1.38)1.83 (1.42 to 2.37)
1 (n=70, 69)0.32 (0.26 to 0.38)0.39 (0.32 to 0.47)
3 (n=65, 63)0.17 (0.12 to 0.25)0.27 (0.18 to 0.40)
5 (n=69, 69)1.34 (1.07 to 1.68)1.97 (1.60 to 2.41)
6A (n=71, 71)1.41 (1.09 to 1.82)2.10 (1.64 to 2.70)
7F (n=71, 70)0.60 (0.50 to 0.71)0.67 (0.57 to 0.80)
19A (n=71, 71)2.33 (1.76 to 3.10)4.36 (3.40 to 5.61)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.80 · 95% CI 0.61 to 1.03
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.53 · 95% CI 0.38 to 0.76
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.74 · 95% CI 0.54 to 1.03
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.77 · 95% CI 0.51 to 1.17
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.56 · 95% CI 0.40 to 0.78
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.45 · 95% CI 0.29 to 0.71
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.56 · 95% CI 0.38 to 0.83
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.82 · 95% CI 0.63 to 1.07
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.66 · 95% CI 0.39 to 1.11
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.68 · 95% CI 0.50 to 0.92
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.67 · 95% CI 0.47 to 0.95
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.89 · 95% CI 0.70 to 1.13
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmc ratio: 0.53 · 95% CI 0.37 to 0.78
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Infant Series: Group 1A, 1B, 1C

Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
1 Month After Infant Series
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Infant Series: Group 1A, 1B, 1C
mcg/mL13vPnC (Group 1A)13vPnC (Group 1B)13vPnC (Group 1C)
4 (n=24, 50, 25)2.50 (1.92 to 3.24)1.86 (1.47 to 2.37)1.73 (1.20 to 2.49)
6B (n=24, 50, 25)1.23 (0.74 to 2.07)0.61 (0.42 to 0.88)0.62 (0.30 to 1.31)
9V (n=24, 50, 25)1.44 (1.02 to 2.03)1.25 (1.02 to 1.53)1.14 (0.78 to 1.65)
14 (n=24, 50, 25)8.95 (6.44 to 12.42)7.13 (5.65 to 8.98)6.95 (4.20 to 11.50)
18C (n=24, 50, 25)2.58 (1.97 to 3.37)1.78 (1.44 to 2.19)1.72 (1.22 to 2.43)
19F (n=24, 50, 25)2.46 (1.77 to 3.43)2.06 (1.67 to 2.55)2.28 (1.61 to 3.24)
23F (n=24, 50, 25)1.38 (0.84 to 2.27)0.65 (0.48 to 0.89)0.95 (0.66 to 1.35)
1 (n=24, 50, 25)1.56 (1.12 to 2.18)1.21 (0.96 to 1.52)1.10 (0.75 to 1.60)
3 (n=24, 50, 25)1.28 (0.86 to 1.90)0.75 (0.60 to 0.93)0.67 (0.49 to 0.91)
5 (n=24, 50, 25)0.85 (0.57 to 1.28)0.50 (0.36 to 0.69)0.46 (0.26 to 0.82)
6A (n=24, 49, 25)1.74 (1.19 to 2.55)1.15 (0.84 to 1.57)0.98 (0.59 to 1.65)
7F (n=24, 50, 25)2.43 (1.56 to 3.77)1.99 (1.61 to 2.46)2.18 (1.55 to 3.06)
19A (n=24, 50, 25)3.43 (2.52 to 4.67)2.60 (2.08 to 3.25)2.88 (2.06 to 4.02)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose: Group 1A, 1B, 1C

Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
Before Toddler Dose (pre-vaccination)
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Before Toddler Dose: Group 1A, 1B, 1C
mcg/mL13vPnC (Group 1A)13vPnC (Group 1B)13vPnC (Group 1C)
4 (n= 20, 44, 21)0.37 (0.27 to 0.50)0.28 (0.22 to 0.36)0.32 (0.22 to 0.46)
6B (n= 20, 42, 20)0.59 (0.42 to 0.83)0.42 (0.31 to 0.56)0.49 (0.30 to 0.80)
9V (n= 20, 44, 21)0.43 (0.30 to 0.60)0.36 (0.28 to 0.46)0.44 (0.33 to 0.60)
14 (n=20, 44, 21)2.48 (1.74 to 3.54)1.83 (1.40 to 2.38)2.04 (1.33 to 3.12)
18C (n=20, 44, 21)0.35 (0.25 to 0.48)0.30 (0.24 to 0.36)0.34 (0.24 to 0.49)
19F (n=20, 44, 21)0.96 (0.57 to 1.61)0.58 (0.48 to 0.71)0.67 (0.52 to 0.87)
23F (n=20, 41, 20)0.31 (0.19 to 0.52)0.21 (0.14 to 0.32)0.24 (0.14 to 0.41)
1 (n=20, 44, 21)0.37 (0.27 to 0.52)0.39 (0.32 to 0.48)0.42 (0.30 to 0.61)
3 (n=20, 44, 20)0.13 (0.07 to 0.24)0.06 (0.04 to 0.08)0.05 (0.02 to 0.09)
5 (n=19, 43, 20)0.75 (0.56 to 1.01)0.71 (0.55 to 0.90)0.81 (0.62 to 1.06)
6A (n=20, 44, 21)0.66 (0.46 to 0.93)0.49 (0.38 to 0.63)0.55 (0.35 to 0.85)
7F (n=20, 44, 21)0.71 (0.55 to 0.92)0.64 (0.54 to 0.77)0.91 (0.69 to 1.19)
19A (n=20, 44, 21)1.20 (0.76 to 1.89)0.72 (0.57 to 0.91)0.92 (0.66 to 1.30)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose: Group 1A, 1B, 1C

Geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) were presented. GMC (13vPnC) and corresponding 2-sided 95% CI were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. Here 'n' signifies participants with a determinate IgG concentration to the given serotype for each arm, respectively.

Time frame:
1 Month After Toddler Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Toddler Dose: Group 1A, 1B, 1C
mcg/mL13vPnC (Group 1A)13vPnC (Group 1B)13vPnC (Group 1C)
4 (n= 21, 45, 20)3.58 (2.66 to 4.83)2.87 (2.29 to 3.59)1.41 (1.05 to 1.88)
6B (n= 21, 45, 20)6.28 (4.60 to 8.58)4.28 (3.18 to 5.75)3.29 (2.24 to 4.84)
9V (n= 21, 45, 20)2.99 (2.26 to 3.96)2.23 (1.81 to 2.74)1.88 (1.41 to 2.52)
14 (n=21, 45, 20)13.20 (9.65 to 18.05)8.84 (6.58 to 11.90)7.01 (5.15 to 9.54)
18C (n=21, 45, 20)3.71 (2.77 to 4.97)2.40 (1.95 to 2.96)1.45 (1.05 to 2.00)
19F (n=21, 45, 20)10.45 (8.20 to 13.32)7.39 (5.62 to 9.71)5.12 (3.91 to 6.72)
23F (n=21, 45, 20)3.57 (2.54 to 5.02)2.41 (1.80 to 3.21)1.71 (1.12 to 2.62)
1 (n=21, 45, 20)4.78 (3.61 to 6.34)3.31 (2.62 to 4.18)2.28 (1.74 to 2.99)
3 (n=21, 44, 20)0.88 (0.61 to 1.25)0.51 (0.41 to 0.64)0.31 (0.23 to 0.43)
5 (n=21, 45, 20)3.41 (2.69 to 4.32)2.66 (2.14 to 3.30)1.95 (1.54 to 2.47)
6A (n=21, 45, 20)6.95 (5.18 to 9.33)5.81 (4.68 to 7.22)4.23 (3.22 to 5.56)
7F (n=21, 45, 20)5.29 (4.11 to 6.80)4.09 (3.41 to 4.89)3.69 (2.84 to 4.80)
19A (n=21, 45, 20)8.63 (6.51 to 11.43)5.28 (3.96 to 7.04)3.96 (3.17 to 4.96)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose: Group 1A, 1B, 1C

The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 Year After Toddler Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 1 Year After Toddler Dose: Group 1A, 1B, 1C
mcg/mL13vPnC (Group 1A)13vPnC (Group 1B)13vPnC (Group 1C)
4 (n=18, 43, 19)0.30 (0.19 to 0.46)0.29 (0.23 to 0.37)0.32 (0.21 to 0.49)
6B (n=18, 43, 19)1.49 (0.84 to 2.66)1.28 (0.96 to 1.70)1.06 (0.70 to 1.60)
9V (n=18, 43, 19)0.59 (0.37 to 0.93)0.56 (0.42 to 0.75)0.80 (0.40 to 1.59)
14 (n=18, 42, 19)1.37 (0.86 to 2.19)1.38 (1.09 to 1.75)1.62 (0.83 to 3.16)
18C (n=18, 43, 19)0.39 (0.26 to 0.57)0.31 (0.24 to 0.41)0.32 (0.17 to 0.59)
19F (n=18, 43, 19)1.27 (0.81 to 2.00)0.89 (0.70 to 1.14)0.86 (0.62 to 1.21)
23F (n=18, 42, 19)0.79 (0.50 to 1.26)0.54 (0.40 to 0.74)0.53 (0.30 to 0.91)
1 (n=18, 41, 19)0.39 (0.30 to 0.50)0.38 (0.32 to 0.47)0.45 (0.31 to 0.64)
3 (n=18, 41, 19)0.17 (0.10 to 0.29)0.12 (0.09 to 0.17)0.11 (0.05 to 0.23)
5 (n=18, 42, 19)0.87 (0.59 to 1.28)1.24 (0.93 to 1.64)1.05 (0.77 to 1.44)
6A (n=18, 43, 19)1.17 (0.73 to 1.87)1.05 (0.80 to 1.40)1.07 (0.72 to 1.59)
7F (n=18, 42, 19)0.65 (0.47 to 0.91)0.65 (0.52 to 0.81)0.81 (0.61 to 1.08)
19A (n=18, 43, 19)2.12 (0.90 to 5.01)1.50 (1.05 to 2.14)1.45 (0.95 to 2.21)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose: Group 1A, 1B, 1C

The persistence of the antibody response induced by 13vPnC was described by geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMCs were calculated using all participants with available data for the specified blood draw. CIs were calculated as back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
2 Years After Toddler Dose
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Persistence 2 Years After Toddler Dose: Group 1A, 1B, 1C
mcg/mL13vPnC (Group 1A)13vPnC (Group 1B)13vPnC (Group 1C)
4 (n=17, 35, 18)0.17 (0.11 to 0.28)0.19 (0.16 to 0.24)0.21 (0.13 to 0.33)
6B (n=17, 35, 18)1.39 (0.81 to 2.40)1.81 (1.28 to 2.56)0.96 (0.58 to 1.60)
9V (n=17, 36, 18)0.68 (0.39 to 1.17)0.83 (0.59 to 1.16)0.63 (0.36 to 1.12)
14 (n=17, 35, 18)1.27 (0.59 to 2.76)1.02 (0.71 to 1.48)0.96 (0.47 to 1.96)
18C (n=16, 35, 18)0.34 (0.18 to 0.65)0.35 (0.23 to 0.52)0.26 (0.16 to 0.44)
19F (n=17, 36, 18)1.53 (0.83 to 2.81)0.93 (0.68 to 1.28)1.13 (0.50 to 2.53)
23F (n=17, 36, 18)1.14 (0.60 to 2.15)1.41 (0.95 to 2.09)0.50 (0.27 to 0.90)
1 (n=17, 35, 18)0.32 (0.23 to 0.44)0.35 (0.26 to 0.47)0.26 (0.18 to 0.39)
3 (n=16, 33, 16)0.20 (0.10 to 0.39)0.19 (0.11 to 0.30)0.14 (0.06 to 0.34)
5 (n=17, 35, 17)1.18 (0.67 to 2.11)1.67 (1.25 to 2.25)0.97 (0.62 to 1.50)
6A (n=17, 36, 18)1.32 (0.87 to 1.99)1.58 (1.10 to 2.26)1.20 (0.63 to 2.30)
7F (n=17, 36, 18)0.61 (0.39 to 0.96)0.68 (0.54 to 0.84)0.46 (0.32 to 0.67)
19A (n=17, 36, 18)3.04 (1.64 to 5.64)2.46 (1.69 to 3.58)1.64 (0.83 to 3.23)
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Infant Series

Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

Time frame:
1 Month After Infant Series
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Infant Series
titer13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n=58, 62)1231 (986.5 to 1537.3)923 (746.9 to 1139.7)
6B (n=51, 61)835 (478.6 to 1455.2)732 (494.0 to 1086.0)
9V (n=54, 60)151 (70.8 to 321.1)211 (108.2 to 413.4)
14 (n=55, 66)1298 (968.3 to 1740.3)1033 (735.7 to 1451.0)
18C (n=56, 63)2931 (2341.2 to 3669.3)2057 (1594.0 to 2655.1)
19F (n= 55, 58)417 (330.7 to 525.8)335 (237.2 to 472.3)
23F (n=55, 60)733 (539.3 to 997.3)582 (413.7 to 817.8)
1 (n=88, 87)10 (8.0 to 13.4)13 (10.0 to 16.8)
3 (n=83, 86)61 (51.2 to 73.2)57 (46.3 to 69.5)
5 (n=83, 85)37 (25.9 to 53.9)64 (47.2 to 86.9)
6A (n=88, 88)1566 (1312.3 to 1869.0)1287 (980.1 to 1691.1)
7F (n=93, 86)1605 (1277.9 to 2014.7)1539 (1297.4 to 1826.3)
19A (n=92, 86)283 (232.4 to 344.1)244 (204.1 to 290.6)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.3 · 95% CI 0.99 to 1.81
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.1 · 95% CI 0.59 to 2.20
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.26 to 1.93
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.3 · 95% CI 0.80 to 1.98
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.4 · 95% CI 1.01 to 2.00
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.2 · 95% CI 0.82 to 1.89
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.3 · 95% CI 0.80 to 1.99
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.8 · 95% CI 0.56 to 1.15
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.1 · 95% CI 0.83 to 1.41
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.36 to 0.94
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.2 · 95% CI 0.88 to 1.68
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.0 · 95% CI 0.78 to 1.39
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.2 · 95% CI 0.89 to 1.51
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Before Toddler Dose

Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

Time frame:
Before the toddler dose (pre-vaccination)
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Before Toddler Dose
titer13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 56, 59)10 (6.0 to 15.3)13 (7.9 to 21.9)
6B (n= 59, 62)12 (6.8 to 20.1)15 (8.5 to 25.6)
9V (n=52, 63)11 (6.2 to 20.9)7 (4.9 to 11.1)
14 (n= 60, 55)242 (148.5 to 394.0)389 (260.4 to 582.2)
18C (n= 54, 58)32 (16.1 to 61.7)51 (26.8 to 98.3)
19F (n= 57, 60)6 (4.1 to 7.4)4 (3.8 to 4.7)
23F (n=59, 62)11 (6.9 to 19.0)16 (9.6 to 26.6)
1 (n=76, 80)6 (4.5 to 6.8)4 (3.9 to 4.8)
3 (n=73, 77)8 (6.2 to 10.0)8 (6.6 to 10.4)
5 (n=74, 79)5 (4.2 to 6.0)5 (4.2 to 5.6)
6A (n=69, 76)45 (25.2 to 81.1)91 (56.6 to 146.3)
7F (n=75, 79)228 (137.6 to 377.1)188 (109.3 to 323.1)
19A (n=77, 79)9 (6.3 to 12.0)10 (7.1 to 14.8)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.37 to 1.44
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.8 · 95% CI 0.37 to 1.71
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.5 · 95% CI 0.76 to 3.12
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.33 to 1.17
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.24 to 1.55
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.3 · 95% CI 0.97 to 1.77
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.35 to 1.46
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.3 · 95% CI 1.00 to 1.60
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.0 · 95% CI 0.68 to 1.33
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.0 · 95% CI 0.82 to 1.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.5 · 95% CI 0.24 to 1.04
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.2 · 95% CI 0.58 to 2.53
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.8 · 95% CI 0.52 to 1.37
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Toddler Dose

Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

Time frame:
1 Month After Toddler Dose
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Month After Toddler Dose
titer13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 67, 61)1154 (879.2 to 1514.5)1757 (1329.1 to 2322.4)
6B (n= 64, 61)1229 (877.2 to 1722.1)1406 (1003.4 to 1970.3)
9V (n=60, 58)1871 (1217.8 to 2873.6)2542 (1711.6 to 3775.2)
14 (n= 62, 62)1294 (969.0 to 1728.4)1651 (1300.1 to 2097.1)
18C (n= 62, 63)2464 (1696.0 to 3579.4)4510 (3399.7 to 5981.7)
19F (n= 61, 62)376 (229.1 to 617.1)640 (431.5 to 948.3)
23F (n=65, 63)1048 (738.6 to 1488.0)1657 (1217.7 to 2255.0)
1 (n=80, 83)59 (43.7 to 78.6)107 (83.0 to 137.0)
3 (n=78, 79)114 (97.1 to 132.7)121 (103.4 to 140.4)
5 (n=80, 83)166 (127.9 to 216.3)260 (203.9 to 331.9)
6A (n=78, 74)1978 (1571.5 to 2489.7)3154 (2606.0 to 3816.0)
7F (n=81, 82)2915 (2453.4 to 3462.7)3154 (2746.2 to 3622.4)
19A (n=81, 82)558 (456.3 to 682.6)825 (692.4 to 983.8)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.45 to 0.97
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.9 · 95% CI 0.54 to 1.40
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.41 to 1.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.8 · 95% CI 0.54 to 1.14
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.5 · 95% CI 0.34 to 0.87
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.31 to 1.10
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.40 to 1.01
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.5 · 95% CI 0.38 to 0.81
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.9 · 95% CI 0.76 to 1.17
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.45 to 0.91
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.47 to 0.85
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.9 · 95% CI 0.74 to 1.15
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.52 to 0.88
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Year After Toddler Dose

Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured centrally using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

Time frame:
1 Year After Toddler Dose
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 1 Year After Toddler Dose
titer13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 66, 59)24 (12.9 to 45.5)29 (15.2 to 54.5)
6B (n= 65, 59)38 (19.0 to 74.9)36 (19.2 to 68.8)
9V (n=61, 63)141 (67.5 to 293.1)244 (126.3 to 469.7)
14 (n= 59, 54)276 (169.0 to 449.4)372 (236.1 to 586.5)
18C (n= 62, 60)33 (16.4 to 67.4)121 (56.9 to 258.1)
19F (n= 67, 57)11 (6.2 to 17.7)18 (9.6 to 35.4)
23F (n=67, 62)45 (23.7 to 86.6)168 (92.4 to 303.9)
1 (n=76, 74)5 (4.2 to 6.3)5 (4.3 to 5.8)
3 (n=76, 70)11 (8.6 to 15.4)13 (9.2 to 18.7)
5 (n=72, 70)8 (5.6 to 10.4)10 (7.0 to 13.3)
6A (n=70, 70)98 (53.0 to 183.0)255 (152.9 to 424.8)
7F (n=71, 71)599 (411.0 to 873.3)533 (348.3 to 814.1)
19A (n=74, 73)28 (17.2 to 43.9)54 (34.2 to 85.5)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.8 · 95% CI 0.35 to 2.05
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.0 · 95% CI 0.41 to 2.63
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.22 to 1.53
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.38 to 1.44
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.3 · 95% CI 0.10 to 0.76
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.25 to 1.30
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.3 · 95% CI 0.11 to 0.65
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.0 · 95% CI 0.81 to 1.32
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.9 · 95% CI 0.56 to 1.37
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.8 · 95% CI 0.51 to 1.23
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.4 · 95% CI 0.17 to 0.86
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.1 · 95% CI 0.64 to 1.97
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.5 · 95% CI 0.27 to 0.97
SecondarySerotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 2 Years After Toddler Dose

Antibody-mediated serum OPA against the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) was measured using a pneumococcal OPA assay. Results were expressed as OPA titers. OPA titers were logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs).

Time frame:
2 Years After Toddler Dose
Reported as:
Geometric mean · titer
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) 2 Years After Toddler Dose
titer13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 46, 54)15 (7.0 to 32.9)17 (9.0 to 32.6)
6B (n= 56, 48)29 (13.7 to 59.9)27 (12.4 to 58.2)
9V (n=50, 55)132 (57.5 to 301.5)75 (34.7 to 163.7)
14 (n= 49, 45)262 (142.0 to 482.8)296 (161.6 to 543.8)
18C (n= 56, 56)14 (7.1 to 25.9)29 (14.3 to 57.9)
19F (n= 60, 58)13 (7.4 to 22.5)20 (10.1 to 39.9)
23F (n=58, 59)60 (29.7 to 122.2)135 (71.2 to 255.3)
1 (n=70, 68)5 (4.1 to 5.4)4 (3.9 to 4.6)
3 (n=69, 66)11 (8.1 to 15.2)16 (10.7 to 24.2)
5 (n=68, 69)5 (4.1 to 5.6)7 (5.4 to 9.4)
6A (n=68, 62)42 (21.5 to 81.1)102 (53.7 to 193.4)
7F (n=64, 65)170 (87.7 to 330.9)269 (155.6 to 463.7)
19A (n=68, 67)22 (13.6 to 37.1)50 (30.1 to 82.6)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.9 · 95% CI 0.33 to 2.37
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.1 · 95% CI 0.37 to 3.07
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.7 · 95% CI 0.57 to 5.36
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.9 · 95% CI 0.38 to 2.07
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.5 · 95% CI 0.18 to 1.21
  • 13vPnC Group 1 (Preterm Infant) · Gmt ratio: 0.6 · 95% CI 0.27 to 1.53
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.4 · 95% CI 0.17 to 1.15
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 1.1 · 95% CI 0.96 to 1.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.41 to 1.14
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.7 · 95% CI 0.49 to 0.92
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.4 · 95% CI 0.16 to 1.03
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.6 · 95% CI 0.27 to 1.48
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Gmt ratio: 0.5 · 95% CI 0.22 to 0.91
SecondaryPercentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series

Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

Time frame:
1 Month After Infant Series
Reported as:
Number · percentage of participants
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Infant Series
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 58, 62)100.00 (93.84 to 100.00)100.00 (94.22 to 100.00)
6B (n= 51, 61)90.20 (78.59 to 96.74)95.08 (86.29 to 98.97)
9V (n= 54, 60)64.81 (50.62 to 77.32)71.67 (58.56 to 82.55)
14 (n= 55, 66)100.00 (93.51 to 100.00)96.97 (89.48 to 99.63)
18C (n= 56, 63)100.00 (93.62 to 100.00)100.00 (94.31 to 100.00)
19F (n= 55, 58)100.00 (93.51 to 100.00)96.55 (88.09 to 99.58)
23F (n= 55, 60)98.18 (90.28 to 99.95)96.67 (88.47 to 99.59)
1 (n= 88, 87)40.91 (30.54 to 51.91)51.72 (40.75 to 62.58)
3 (n=83, 86)100.00 (95.65 to 100.00)95.35 (88.52 to 98.72)
5 (n= 83, 85)67.47 (56.30 to 77.35)83.53 (73.91 to 90.69)
6A (n= 88, 88)100.00 (95.89 to 100.00)97.73 (92.03 to 99.72)
7F (n= 93, 86)97.85 (92.45 to 99.74)100.00 (95.80 to 100.00)
19A (n= 92, 86)98.91 (94.09 to 99.97)100.00 (95.80 to 100.00)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -6.33 to 5.99
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -4.89 · 95% CI -16.87 to 5.39
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -6.85 · 95% CI -24.28 to 10.67
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 3.03 · 95% CI -3.68 to 10.57
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -6.57 to 5.88
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 3.45 · 95% CI -3.32 to 11.91
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 1.52 · 95% CI -6.73 to 9.94
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Perecent difference: -10.82 · 95% CI -25.51 to 4.34
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 4.65 · 95% CI 0.04 to 11.48
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -16.06 · 95% CI -29.15 to -2.60
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 2.27 · 95% CI -1.96 to 7.97
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -2.15 · 95% CI -7.55 to 2.10
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.09 · 95% CI -5.96 to 3.18
SecondaryPercentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) Before Toddler Dose

Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

Time frame:
Before Toddler Dose (pre-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) Before Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n=56, 59)21.43 (11.59 to 34.44)30.51 (19.19 to 43.87)
6B (n=59, 62)22.03 (12.29 to 34.73)27.42 (16.85 to 40.23)
9V (n=52, 63)19.23 (9.63 to 32.53)12.70 (5.65 to 23.50)
14 (n=60, 55)86.67 (75.41 to 94.06)94.55 (84.88 to 98.86)
18C (n=54, 58)44.44 (30.92 to 58.60)55.17 (41.54 to 68.26)
19F (n=57, 60)8.77 (2.91 to 19.30)1.67 (0.04 to 8.94)
23F (n=59, 62)23.73 (13.62 to 36.59)37.10 (25.16 to 50.31)
1 (n=76, 80)11.84 (5.56 to 21.29)3.75 (0.78 to 10.57)
3 (n=73, 77)32.88 (22.33 to 44.87)40.26 (29.23 to 52.06)
5 (n=74, 79)8.11 (3.03 to 16.82)7.59 (2.84 to 15.80)
6A (n=69, 76)52.17 (39.80 to 64.35)72.37 (60.91 to 82.01)
7F (n=75, 79)78.67 (67.68 to 87.29)73.42 (62.28 to 82.73)
19A (n=77, 79)25.97 (16.64 to 37.23)29.11 (19.43 to 40.42)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -9.08 · 95% CI -25.11 to 7.49
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -5.39 · 95% CI -21.03 to 10.40
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 6.53 · 95% CI -7.16 to 21.16
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -7.88 · 95% CI -20.28 to 3.35
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -10.73 · 95% CI -29.01 to 8.11
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 7.11 · 95% CI -1.52 to 17.65
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -13.37 · 95% CI -29.57 to 3.31
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 8.09 · 95% CI -0.52 to 17.81
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -7.38 · 95% CI -22.86 to 8.29
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.51 · 95% CI -8.82 to 10.08
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -20.19 · 95% CI -35.45 to -3.95
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 5.25 · 95% CI -8.50 to 19.06
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -3.14 · 95% CI -17.51 to 11.13
SecondaryPercentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Toddler Dose

Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

Time frame:
1 Month After Toddler Dose
Reported as:
Number · percentage of participants
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Month After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 67, 61)100.00 (94.64 to 100.00)100.00 (94.13 to 100.00)
6B (n= 64, 61)98.44 (91.60 to 99.96)98.36 (91.20 to 99.96)
9V (n= 60, 58)95.00 (86.08 to 98.96)96.55 (88.09 to 99.58)
14 (n= 62, 62)100.00 (94.22 to 100.00)100.00 (94.22 to 100.00)
18C (n= 62, 63)98.39 (91.34 to 99.96)100.00 (94.31 to 100.00)
19F (n= 61, 62)88.52 (77.78 to 95.26)95.16 (86.50 to 98.99)
23F (n= 65, 63)98.46 (91.72 to 99.96)98.41 (91.47 to 99.96)
1 (n= 80, 83)87.50 (78.21 to 93.84)93.98 (86.50 to 98.02)
3 (n=78, 79)100.00 (95.38 to 100.00)98.73 (93.15 to 99.97)
5 (n= 80, 83)96.25 (89.43 to 99.22)97.59 (91.57 to 99.71)
6A (n=78, 74)100.00 (95.38 to 100.00)100.00 (95.14 to 100.00)
7F (n= 81, 82)100.00 (95.55 to 100.00)100.00 (95.60 to 100.00)
19A (n= 81, 82)100.00 (95.55 to 100.00)100.00 (95.60 to 100.00)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -5.59 to 5.89
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.08 · 95% CI -6.81 to 7.37
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.55 · 95% CI -10.87 to 7.44
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -5.94 to 5.94
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.61 · 95% CI -8.66 to 4.25
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -6.64 · 95% CI -17.93 to 3.56
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.05 · 95% CI -6.74 to 7.04
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -6.48 · 95% CI -16.37 to 2.75
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 1.27 · 95% CI -3.37 to 6.85
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.34 · 95% CI -8.36 to 5.14
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.73 to 5.04
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.48 to 4.55
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.00 · 95% CI -4.48 to 4.55
SecondaryPercentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Year After Toddler Dose

Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

Time frame:
1 Year After Toddler Dose
Reported as:
Number · percentage of participants
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 1 Year After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 66, 59)34.8 (23.5 to 47.6)42.4 (29.6 to 55.9)
6B (n= 65, 59)41.5 (29.4 to 54.4)47.5 (34.3 to 60.9)
9V (n= 61, 63)62.3 (49.0 to 74.4)73.0 (60.3 to 83.4)
14 (n= 59, 54)86.4 (75.0 to 94.0)90.7 (79.7 to 96.9)
18C (n= 62, 60)38.7 (26.6 to 51.9)61.7 (48.2 to 73.9)
19F (n= 67, 57)17.9 (9.6 to 29.2)29.8 (18.4 to 43.4)
23F (n= 67, 62)49.3 (36.8 to 61.8)77.4 (65.0 to 87.1)
1 (n= 76, 74)10.5 (4.7 to 19.7)10.8 (4.8 to 20.2)
3 (n=76, 70)47.4 (35.8 to 59.2)48.6 (36.4 to 60.8)
5 (n= 72, 70)20.8 (12.2 to 32.0)31.4 (20.9 to 43.6)
6A (n=70, 70)62.9 (50.5 to 74.1)81.4 (70.3 to 89.7)
7F (n= 71, 71)93.0 (84.3 to 97.7)90.1 (80.7 to 95.9)
19A (n= 74, 73)54.1 (42.1 to 65.7)72.6 (60.9 to 82.4)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -7.5 · 95% CI -24.5 to 9.9
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -5.9 · 95% CI -23.6 to 11.8
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -10.7 · 95% CI -27.6 to 6.0
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -4.3 · 95% CI -17.0 to 8.4
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -23.0 · 95% CI -40.0 to -4.9
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -11.9 · 95% CI -27.4 to 3.4
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -28.2 · 95% CI -43.9 to -11.0
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -0.3 · 95% CI -10.9 to 10.3
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -1.2 · 95% CI -17.5 to 15.1
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -10.6 · 95% CI -25.3 to 4.5
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -18.6 · 95% CI -33.3 to -3.0
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 2.8 · 95% CI -7.1 to 13.1
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -18.5 · 95% CI -33.7 to -2.8
SecondaryPercentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 2 Years After Toddler Dose

Percentage of participants achieving OPA titer \>=LLOQ for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) determined in blood samples of all participants was presented. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13.

Time frame:
2 Years After Toddler Dose
Reported as:
Number · percentage of participants
Percentage of Participants With OPA Titer >= Lower Limit of Quantitation (LLOQ) 2 Years After Toddler Dose
percentage of participants13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)
4 (n= 46, 54)21.7 (10.9 to 36.4)29.6 (18.0 to 43.6)
6B (n= 56, 48)35.7 (23.4 to 49.6)35.4 (22.2 to 50.5)
9V (n= 50, 55)60.0 (45.2 to 73.6)52.7 (38.8 to 66.3)
14 (n= 49, 45)81.6 (68.0 to 91.2)84.4 (70.5 to 93.5)
18C (n= 56, 56)21.4 (11.6 to 34.4)39.3 (26.5 to 53.2)
19F (n= 60, 58)25.0 (14.7 to 37.9)29.3 (18.1 to 42.7)
23F (n= 58, 59)53.4 (39.9 to 66.7)74.6 (61.6 to 85.0)
1 (n= 70, 68)8.6 (3.2 to 17.7)2.9 (0.4 to 10.2)
3 (n=69, 66)46.4 (34.3 to 58.8)51.5 (38.9 to 64.0)
5 (n= 68, 69)7.4 (2.4 to 16.3)21.7 (12.7 to 33.3)
6A (n=68, 62)44.1 (32.1 to 56.7)64.5 (51.3 to 76.3)
7F (n= 64, 65)68.8 (55.9 to 79.8)80.0 (68.2 to 88.9)
19A (n= 68, 67)45.6 (33.5 to 58.1)67.2 (54.6 to 78.2)
Statistical analysis
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -7.9 · 95% CI -25.2 to 9.9
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 0.3 · 95% CI -18.5 to 19.0
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 7.3 · 95% CI -12.0 to 26.2
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -2.8 · 95% CI -19.1 to 13.3
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -17.9 · 95% CI -34.6 to -0.3
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -4.3 · 95% CI -20.6 to 12.1
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -21.1 · 95% CI -37.8 to -3.2
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: 5.6 · 95% CI -2.7 to 15.2
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -5.1 · 95% CI -22.0 to 12.0
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -14.4 · 95% CI -26.7 to -2.4
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -20.4 · 95% CI -36.8 to -3.0
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -11.3 · 95% CI -26.4 to 4.1
  • 13vPnC Group 1 (Preterm Infant) vs 13vPnC Group 2 (Term Infant) · Percent difference: -21.6 · 95% CI -37.7 to -4.6

Adverse events

Collected over AEs/SAEs: recorded from 13vPnC infant dose 1 to 2-year follow-up after toddler dose. Participants recorded pre-specified AEs in electronic diary: local reactions; systemic events (up to 7 days after each vaccine dose). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Group 1 (Preterm Infant) - Infant Series—14/100 (14%)98/100 (98%)
13vPnC Group 2 (Term Infant) - Infant Series—5/100 (5%)99/100 (99%)
13vPnC Group 1 (Preterm Infant) - After Infant Series—8/100 (8%)13/100 (13%)
13vPnC Group 2 (Term Infant) - After Infant Series—9/100 (9%)11/100 (11%)
13vPnC Group 1 (Preterm Infant) - Toddler Dose—2/99 (2%)93/99 (93.9%)
13vPnC Group 2 (Term Infant) - Toddler Dose—1/97 (1%)92/97 (94.8%)
13vPnC Group 1 (Preterm Infant) - 1 Year Follow-up—13/99 (13.1%)2/99 (2%)
13vPnC Group 2 (Term Infant) - 1 Year Follow-up—8/97 (8.2%)0/97 (0%)
13vPnC Group 1 (Preterm Infant) - 2 Year Follow-up—6/88 (6.8%)1/88 (1.1%)
13vPnC Group 2 (Term Infant) - 2 Year Follow-up—8/88 (9.1%)1/88 (1.1%)
Most frequent serious events
Showing 10 of 44
Most frequent serious events
Event13vPnC Group 1 (Preterm Infant) - Infant Series13vPnC Group 2 (Term Infant) - Infant Series13vPnC Group 1 (Preterm Infant) - After Infant Series13vPnC Group 2 (Term Infant) - After Infant Series13vPnC Group 1 (Preterm Infant) - Toddler Dose13vPnC Group 2 (Term Infant) - Toddler Dose13vPnC Group 1 (Preterm Infant) - 1 Year Follow-up13vPnC Group 2 (Term Infant) - 1 Year Follow-up13vPnC Group 1 (Preterm Infant) - 2 Year Follow-up13vPnC Group 2 (Term Infant) - 2 Year Follow-up
PneumoniaInfections and infestations2/1001/1003/1000/1000/990/974/990/970/882/88
BronchiolitisInfections and infestations4/1002/1001/1000/1001/990/971/990/970/880/88
BronchopneumoniaInfections and infestations0/1000/1001/1003/1000/990/971/990/970/881/88
Cerebral palsyCongenital, familial and genetic disorders0/1000/1000/1000/1000/990/970/990/972/880/88
IntussusceptionGastrointestinal disorders0/1000/1000/1000/1000/990/970/992/970/880/88
BronchitisInfections and infestations0/1001/1000/1002/1000/990/972/990/971/881/88
Respiratory tract infectionInfections and infestations0/1000/1000/1000/1000/990/972/990/970/880/88
Abdominal painGastrointestinal disorders2/1000/1000/1000/1000/990/970/990/970/880/88
GastroenteritisInfections and infestations1/1000/1002/1000/1000/990/971/990/970/880/88
Pneumonia respiratory syncytial viralInfections and infestations2/1000/1000/1000/1001/990/971/990/970/880/88
Most frequent other events
Showing 10 of 155
Most frequent other events
Event13vPnC Group 1 (Preterm Infant) - Infant Series13vPnC Group 2 (Term Infant) - Infant Series13vPnC Group 1 (Preterm Infant) - After Infant Series13vPnC Group 2 (Term Infant) - After Infant Series13vPnC Group 1 (Preterm Infant) - Toddler Dose13vPnC Group 2 (Term Infant) - Toddler Dose13vPnC Group 1 (Preterm Infant) - 1 Year Follow-up13vPnC Group 2 (Term Infant) - 1 Year Follow-up13vPnC Group 1 (Preterm Infant) - 2 Year Follow-up13vPnC Group 2 (Term Infant) - 2 Year Follow-up
Irritability or Decreased Sleep- AnyGeneral disorders85/9574/95————————
Irritability or Decreased Sleep- AnyGeneral disorders80/9580/97——76/9073/91————
Irritability or Decreased Sleep- MildGeneral disorders73/9066/92————————
Irritability or Decreased Sleep- AnyGeneral disorders73/9277/95————————
Irritability or Decreased Sleep- MildGeneral disorders72/9366/95——67/9068/89————
Irritability or Decreased Sleep- MildGeneral disorders65/9068/91————————
Increased Sleep- AnyGeneral disorders63/8557/89————————
Increased Sleep- MildGeneral disorders58/8352/88————————
Tenderness- AnySkin and subcutaneous tissue disorders46/9437/88——60/8647/85————
Increased Sleep- AnyGeneral disorders65/9666/95——48/8356/86————

Baseline characteristics

Safety Analysis set included all participants who received at least 1 dose of 13vPnC.

Age, Continuous
Age, Continuous(months)13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)Total
Mean1.8 ± 0.61.5 ± 0.51.7 ± 0.6
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC Group 1 (Preterm Infant)13vPnC Group 2 (Term Infant)Total
Female4855103
Male524597
08

Study locations

12 sites
  • NZOZ "HIPOKRATES-II" Sp. z o.o.
    Krakow, 31-223, Poland
  • Hanna Czajka Indywidualna Praktyka Specjalistyczna Lekarska
    Krakow, 31-302, Poland
  • SP ZOZ Wojewodzki Specjalistyczny Szpital im. W. Bieganskiego w Lodzi
    Lodz, 91-347, Poland
  • Specjalistyczny ZOZ nad Matka i Dzieckiem
    Poznan, 61-825, Poland
  • Szpital im. Sw. Jadwigi Slaskiej, Oddzial Pediatryczny
    Trzebnica, 55-100, Poland
  • Samodzielny Publiczny Szpital Kliniczny nr 1 we Wroclawiu
    Wroclaw, 50-345, Poland
  • Hospital Universitario de Santiago de Compostela
    Santiago de Compostela, A Coruña 15706, Spain
  • Complexo Hospitalario Xeral Cies
    Vigo, Pontevedra 36204, Spain
  • Complejo Hospitalario DE Torrecardenas
    Almeria, 04009, Spain
  • Hospital 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario de La Paz
    Madrid, 28046, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, 31008, Spain
09

References and documents

Publications

  • Martinon-Torres F, Wysocki J, Center KJ, Czajka H, Majda-Stanislawska E, Omenaca F, Concheiro-Guisan A, Gimenez-Sanchez F, Szenborn L, Blazquez-Gamero D, Moreno-Galarraga L, Giardina PC, Sun G, Gruber WC, Scott DA, Gurtman A. Circulating Antibody 1 and 2 Years After Vaccination With the 13-Valent Pneumococcal Conjugate Vaccine in Preterm Compared With Term Infants. Pediatr Infect Dis J. 2017 Mar;36(3):326-332. doi: 10.1097/INF.0000000000001428. PubMed 27902652 ↗
  • Martinon-Torres F, Czajka H, Center KJ, Wysocki J, Majda-Stanislawska E, Omenaca F, Bernaola Iturbe E, Blazquez Gamero D, Concheiro-Guisan A, Gimenez-Sanchez F, Szenborn L, Giardina PC, Patterson S, Gruber WC, Scott DA, Gurtman A. 13-valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants. Pediatrics. 2015 Apr;135(4):e876-86. doi: 10.1542/peds.2014-2941. Epub 2015 Mar 16. PubMed 25780077 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2010
First posted
Sep 1, 2010
Start
Oct 2010
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Feb 4, 2015
Last update
May 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01193335
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 1, 2010
Start date
Oct 2010
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Feb 4, 2015
Last update
May 11, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion